Verismo Therapeutics

Our own Susan. Howard is a speaker at the Nexus Conference in Piscataway, New Jersey! Join Susan today at 12:20pm as she shares her expertise on the "Challenges with Precision Medicine Studies for Clinical Operations and Data Management." #ClinicalTrials #VerismoTherapeutics #KIRCAR #Biotech #BestTeamEver

Verismo Therapeutics is excited to welcome Olivia Dermody to the Verismo team as Senior Clinical Study Manager! Olivia brings over 7 years of hands-on experience in clinical trial management, particularly with Phase I/II trials in the rare disease space. Her passion for enhancing participant experiences and her dedication to building impactful, high-quality trials are invaluable for our clinical operations team. Olivia holds a Bachelor's degree in Psychology from Temple University. Please join us in welcoming Olivia to the Verismo team! #BestTeamEver #celltherapy #biotech

We were thrilled that Verismo Therapeutics’ Chief Scientific Officer, Dr. Laura Johnson, was honored last night as one of the 2024 Women of Influence. Our team was there to support her at this inspiring event hosted by Philadelphia Business Journal, recognizing the achievements of incredible women across the Greater Philadelphia region. We are immensely proud of Dr. Johnson's contributions to the field of T cell therapy and grateful for her leadership. Congratulations to all of the honorees who are driving innovation and making a meaningful impact in their respective fields! #CARTCellTherapy #VerismoTherapeutics #biotech #KIRCAR #BestTeamEver

We are thrilled to announce the release of a new video by the Mesothelioma Applied Research Foundation featuring Dr. Laura Johnson, Dr. Daniel Sterman, and the work taking place every day at Verismo Therapeutics! In this video, we discuss the potential of CAR T cell therapy in the fight against mesothelioma, highlighting our shared mission to bring hope and cutting-edge solutions to mesothelioma patients. Check it out on YouTube here: https://lnkd.in/e2i7N564 #Mesothelioma #CARTCellTherapy #VerismoTherapeutics #CancerResearch #InnovationInHealthcare #KIRCAR #biotech #BestTeamEver

Verismo Therapeutics is pleased to announce the activation of our CELESTIAL-301 Phase 1 clinical trial at the Colorado Blood Cancer Institute Medical Group. This trial will evaluate SynKIR™-310, a new treatment for patients with relapsed/refractory B-cell Non-Hodgkin Lymphomas, including DLBCL, Follicular Lymphoma, Mantle Cell Lymphoma, and Marginal Zone Lymphoma. At Verismo, we are committed to advancing CAR T therapies to address the unmet needs of patients who have relapsed after commercial CAR T treatments. SynKIR™-310, based on our KIR-CAR platform, could improve long-term outcomes for these patients. https://lnkd.in/epm5vgCk #KIRCAR #CellTherapy #ClinicalTrials #VerismoTherapeutics #SynKIR #BestTeamEver

Join Raymond Luke, Verismo Therapeutics's Director of MSAT tomorrow morning at the CAR-TCR Summit in Boston. At 9:30am, Raymond will be presenting "Leveraging Modular Automation to Minimize Error while Maintaining Flexibility," and at 11:00am, he will be taking part in a panel discussion titled, "Evaluating Technologies to Boost Productivity, Minimize Error, and Reduce costs." #CARTCR #VerismoTherapeutics #KIRCAR #BestTeamEver

Today is #MesotheliomaAwarenessDay. We at Verismo Therapeutics stand in solidarity with those affected by this rare and aggressive cancer. Together, we can make a difference in the fight against mesothelioma. #MesotheliomaAwarenessDay #celltherapy #VerismoTherapeutics

On #WorldCancerResearchDay, Verismo Therapeutics reaffirms our commitment to advancing CAR T cell therapy. We are grateful to be part of a community dedicated to finding innovative solutions and improving outcomes for patients. Together, through collaboration and continued research, we can bring hope to those affected by cancer. #WorldCancerResearchDay #CancerResearch #VerismoTherapeutics #KIRCAR #biotech #CellTherapy

Join Raymond Luke, Verismo Therapeutics's Director of MSAT tomorrow morning at the CAR-TCR Summit in Boston. At 9:30am, Raymond will be presenting "Leveraging Modular Automation to Minimize Error while Maintaining Flexibility," and at 11:00am, he will be taking part in a panel discussion titled, "Evaluating Technologies to Boost Productivity, Minimize Error, and Reduce costs." #CARTCR #VerismoTherapeutics #KIRCAR #BestTeamEver

We are thrilled to announce that Verismo Therapeutics has been awarded a $150,000 G-Rex® Grant by ScaleReady™! This grant will accelerate the development and optimization of our innovative KIR-CAR platform, helping to enhance our manufacturing processes with the G-Rex® system.   For more information please see the full release:   https://lnkd.in/ebVZx69g   #VerismoTherapeutics #KIRCAR #CellTherapy #CellAndGeneTherapy #ScaleReady #Innovation #CancerResearch #Biotech #BestTeamEver